de Sanjosé S, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018;47:2–13. PMID:28964706.

Article  PubMed  Google Scholar 

Cheng MA, Farmer E, Huang C, Lin J, Hung CF, Wu TC. Therapeutic DNA vaccines for human Papillomavirus and associated diseases. Hum Gene Ther. 2018;29(9):971–96. PMID: 29316817. PMCID: PMC6152857.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Orbegoso C, Murali K, Banerjee S. The current status of immunotherapy for cervical cancer. Rep Pract Oncol Radiother. 2018;23(6):580–588. PMID: 30534022. PMCID: PMC6277269.

Lee SJ, Yang A, Wu TC. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. J Gynecol Oncol. 2016;27(5):e51. PMID: 27329199. PMCID: PMC4944018.

Article  PubMed  PubMed Central  Google Scholar 

Kim TJ, Jin HT, Hur SY, Yang HG. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun. 2014;5:5317. PMID: 25354725. PMCID: PMC4220493.

Article  PubMed  CAS  Google Scholar 

Choi YJ, Hur SY, Kim TJ, A Phase II, Prospective. Randomized, Multicenter, Open-Label Study of GX-188E, an HPV DNA Vaccine, in Patients with Cervical Intraepithelial Neoplasia 3. Clin Cancer Res. 2020;26(7):1616–23. PMID:31727676.

Article  PubMed  CAS  Google Scholar 

Trimble CL, Morrow MP, Kraynyak KA. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasis 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386(10008):2078–2088. PMID: 26386540. PMCID: PMC4888059.

Aggarwal C, Cohen RB, Morrow MP, Kraynyak KA, Sylvester AJ, Knoblock DM, et al. Immunotherapy targeting HPV16/18 generates potent immune responses in HPV-associated head and neck cancer. Clin Cancer Res. 2019;25(1):110–24. PMID: 30242022. PMCID: PMC6320307.

Article  PubMed  CAS  Google Scholar 

Youn JW, Hur SY, Woo JW, Kim YM, Lim MC, Park SY, et al. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. Lancet Oncol. 2020;21(12):1653–60. PMID: 33271094.

Zong JB, PENG QL, WANG QY, et al. Human HSP70 and modified HPV16 E7 fusion DNA vaccine induces enhanced specific CD8+ T cell responses and anti-tumor effects. Oncol Rep. 2009;22(4):953–61. PMID:19724878.

PubMed  CAS  Google Scholar 

Wang QY, Xu YF, Fan DS et al. Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumor activity of DNA vaccine. Zhong guo Yi Xue Ke Xue Yuan Xue Bao. 2007;29(5):584 – 91. (Article in Chinese). PMID: 18051710.

de Oliveira LM, Morale MG, Chaves AA, et al. Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope Vaccine. PLoS ONE. 2015;10(9):e0138686. 2015.PMID: 26390407.

Article  PubMed  PubMed Central  Google Scholar 

Thomas KJ, Smith KL, Youde SJ, et al. HPV16 E6 29-38-specific T cells kill cervical carcinoma cells despite partial evasion of T-cell effector function. Int J Cancer. 2008;122(12):2791–9. PMID: 18366058.

Article  PubMed  CAS  Google Scholar 

Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CM, Kast MW. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 1993;23(9):2242–9. PMID: 7690326.

Article  PubMed  CAS  Google Scholar 

Lipford GB, Bauer S, Wagner H, Heeg K. Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumor antigen, E6. Immunology. 1995;84(2):298–303. PMID: 7751006.

PubMed  PubMed Central  CAS  Google Scholar 

Gao F, Zheng M, Fan J. A trimeric spike-based COVID-19 vaccine candidate induces broad neutralization against SARS-CoV-2 variants. Hum Vaccin Immunother. 2023;19(1):2186110. PMID: 36882925.

Article  PubMed  PubMed Central  Google Scholar 

Kayraklioglu N, Horuluoglu B, Klinman DM. CpG Oligonucleotides as Vaccine Adjuvants. Methods Mol Biol. 2021;2197:51–85. PMID: 32827132.

Article  PubMed  CAS  Google Scholar 

Yu YZ, Ma Y, Xu WH, et al. Combinations of various CpG motifs cloned into plasmid backbone modulate and enhance protective immunity of viral replicon DNA anthrax vaccines. Med Microbiol Immunol. 2015;204:481–91. PMID:25265876.

Article  PubMed  CAS  Google Scholar 

Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines. 2012;11(2):189–209. PMID: 22309668. PMCID: PMC3293989.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Grasse M, Meryk A, Miggitsch C, Grubeck-Loebenstein B. GM-CSF improves the immune response to the diphtheria-component in a multivalent vaccine. Vaccine. 2018;36:4672–80. PMID: 29961602. PMCID: PMC7116485.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Suschak JJ, Shoemaker KBCJ, et al. The Genetic Adjuvants Interleukin-12 and Granulocyte-Macrophage Colony Stimulating Factor Enhance the Immunogenicity of an Ebola Virus Deoxyribonucleic Acid Vaccine in Mice. J Infect Dis. 2018;218(suppl5):S519–S. 527.PMID:30053157.

PubMed  Google Scholar 

Klinman DM, Klaschik S, Sato T, Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious disease. Adv Drug Deliv Rev. 2009;61(3):248–55. PMID:19272313.

Article  PubMed  CAS  Google Scholar 

Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines. 2011;10(4):499–511. PMID: 21506647. PMCID: PMC3108434.

Yu ZY, Li N, Ma Y, et al. Three types of human CpG motifs differentially modulate and augment immunogenicity of nonviral and viral replicon DNA vaccines as built-in adjuvants. Eur J Immunol. 2013;43(1):228–39. PMID: 23037552.

Article  PubMed  CAS  Google Scholar 

Shirota H, Klinman DM. Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Rev Vaccines. 2014;13(2):299–312. PMID: 24308579. PMCID: PMC6335645.

Didierlaurent AM, Laupèze B, Pasquale AD, et al. Adjuvant system AS01:helping to overcome the challenges of modern vaccines. Expert Rev Vaccines. 2017;16(1):55–63. PMID:27448771.

Article  PubMed  CAS  Google Scholar 

Christensen D, et al. Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines. 2011;10(4):513–21. PMID:21506648.

Article  PubMed  CAS  Google Scholar 

Hawkins WG, Trcka J, Segal N, et al. The role of lipopolysaccharide in T-cell responses following DNA vaccination. Vaccine. 2003;21(13–14):1548–53. PMID:12615452.

Article  PubMed  CAS  Google Scholar 

Kianmehr Z, Soleimanjahi H, Ardestani SK, Fotouhi F, Abdoli A. Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice. Med Microbiol Immunol. 2015;204(2):205–13. PMID: 25187406.

Article  PubMed  CAS  Google Scholar 

Li K, Gao L, Gao H, et al. Codon optimization and woodchuck hepatitis virus posttranscriptional regulatory element enhance the immune responses of DNA vaccines against infectious bursal disease virus in chickens. Virus Res. 2013;175(2):120–7. PMID:23631937.

Article  PubMed  CAS  Google Scholar 

Duan F, Chen J, Yao H, et al. Enhanced therapeutic efficacy of Listeria-based cancer vaccine with codon-optimized HPV16 E7. Hum Vaccin Immunother. 2021;17(6):1568–77. PMID:33449866. PMCID: PMC8115762.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li L, Petrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccine. 2016;15(3):313–29. PMID:26707950. PMCID: PMC4955855.

Article  CAS  Google Scholar 

Lambricht L, Vanvarenberg K, Beuckelaer AD, et al. Coadministration of a plasmid encoding HIV-1 Gag Enhances the efficacy of cancer DNA vaccines. Mol Ther. 2016;24(9):1686–96. PMID:27434590. PMCID: PMC5223100.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chen H, Zheng XY, Wang R, et al. Immunization with electroporation enhances the protective effect of a DNA vaccine candidate expressing prME antigen dengue virus serotype 2 infection. Clin Immunol. 2016;171:41–9. PMID:27578400.

Article  PubMed  CAS  Google Scholar 

Li LL, Wang HR, Zhou ZY, et al. One-prime multi-boost strategy immunization with recombinant DNA, adenovirus, and MVA vector. Antiviral Res. 2016;128:20–7. PMID:26821205.

Article  PubMed  CAS  Google Scholar 

Peng SW, Qiu J, Yang A, et al. Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease. Cell Biosci. 2016;6:16. PMID:26918115. PMCID: PMC4766698.